Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight photodynamic therapy for actinic keratoses: ALA vs MAL
2013-002108-15Phase 4Completed
- Sponsor
- Mari Grönroos
- Start
- Jun 2013
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in actinic keratosis (AK) comparing Ameluz daylight PDT with Metvix daylight PDT (2 arms). Primary endpoints: Clinical healing of actinic keratoses and Histological healing of actinic keratoses. Started Jun 2013; status: completed.
02
Drugs
5-aminolevulinic acidmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2013-002108-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002108-15.